

Original research article

River State, Nigeria Statistiques COVID-19 entre avril 2020 et mars 2021 : Analyse des data COVID-19 démographiques, répartition géographique et symptômes couramment présentés de River State, Nigeria entre avril 2020 et mars 2021

Comment [D1]: If it is the hospital or a community health center, you must specify

ABSTRACT

Introduction Objectives: ~~Cette recherche fournit une étude épidémiologique préliminaire de l'épidémie.~~ Analyser les données of COVID-19 in Rivers State, Nigeria entre avril et mars 2021.

Study design : ~~recupération de données secondaires~~

Lieu et durée des études : ~~Département d'épidémiologie du Département de la santé publique de l'État de Rivers, ministère de la Santé en décembre 2022.~~

Methodology : All patients with incomplete data were excluded from the study. Secondary data recorded in Excel were extracted from the Department of Epidemiology, Rivers State Ministry of Health and exported to IBM Statistical Product and Service Solutions (SPSS) version 25 for analysis. Frequencies were generated and reported in tabular form. Ethical approval was obtained from the Board Ethics Committee of the State Ministry of Health, Port Harcourt.

Results : ~~10,5% des données étaient incomplètes.~~ The mortality rate was 1.4%. ~~Y~~ About two-thirds of those infected were in Port Harcourt Local Government Area (LGA) and almost one-third in Obio/Akpor LGA. ~~Y~~ 17.4% of those infected had a positive travel history and 1% attended a funeral before the onset of infection. ~~Quatre~~ [4,843 (76.9%)] out of five confirmed people had symptoms ranging from fever, cough, loss of smell and chest pain, among others. There is a statistical correlation between the sex and age group of infected people (<0.0001). More men were infected than women and those in the age groups 31-40, 41-50 years old. accounted for three-fifths of those infected.

Conclusion : Men were three times more infected than women and the mortality rate was 1.4%.

Comment [D2]: No mention in the abstract, it must start with a brief introduction defining COVID-19

Comment [D3]: This is not part of the abstract

Comment [D4]: Should be in the methodology

Comment [D5]: The type of the study is missing

Comment [D6]: These were already excluded from the study

Comment [D7]: On how many people does this not come out?

Comment [D8]: You should know that it is not a correlation perhaps it could analyze the association being sex and age

Comment [D9]: We need to give a little more detail otherwise it is insufficient.

Keywords: ~~Symptômes courants~~ Analyse, COVID-19, River State, Nigeria, de avril 2020 à mars 2021 ~~Données démographiques, Propagation géographique~~

1. INTRODUCTION

The World Health Organization (WHO) declared the outbreak of the novel coronavirus in Wuhan, China, a global emergency on January 20, 2020.1 It recognized its potential to cause a global pandemic on February 24, 2020 and declared a COVID-19 pandemic on March 11, 2020.1 From a scientific perspective, rarely has a single pathology required the mobilization of as much effort and resources as COVID-19.2 Globally, as of

January 9, 2023, 20.5 million cases of COVID-19 had been confirmed worldwide and 182,000 deaths had been confirmed. reported to the World Health Organization.¹ Additionally, a total of 5.51 billion people worldwide have received one dose of a COVID-19 vaccine (71.8% of the global population.^{3,4} In Africa, as of January 9, 2023, there were 12,216,748 confirmed cases, 256,542 deaths and 801 million vaccine doses administered, with 25.6% of Africans fully vaccinated.^{2,4-6} Infection COVID-19 was first reported in Nigeria on February 27, 2020 and as of January 9, 2023. There have been 266,463 confirmed cases, 3,155 deaths and 28.1% of the population fully vaccinated. 4.7 - 11

On April 21, 2020, the race to develop a COVID-19 vaccine began, and by May 10, 2022, more than 5.16 billion (67.2%) people worldwide would have received at least one dose of the vaccine. against COVID-19. 12 At that time, in Nigeria, less than 35% of the population had received at least one dose of the COVID-19 vaccine and only 7.4% had been fully vaccinated.¹²

Despite the devastating effects of the COVID-19 pandemic on many countries around the world, the impact in some parts of Africa has been less.² ¹³ The effects of the pandemic on the African continent, including Nigeria, have not not been as devastating as in other continents despite predictions that it would be the most vulnerable and hardest hit continent.¹³⁻¹⁷ Thus, many public health experts were perplexed because Africa reported fewer cases and deaths from COVID-19 than expected.¹³ Additionally, most identified cases of COVID-19 cases in Africa were imported from Europe and the United States, rather than the original epicenter of the COVID-19, China.¹⁸

As the rapidly evolving COVID-19 pandemic has placed a heavy burden on health systems, it was expected that the pandemic would be worse in low- and middle-income countries (LMICs) due to weak health systems, limited financial resources and inadequate protective equipment ¹⁹, poor testing and treatment capacities, and a lack of funding for research.¹⁹ However, this was not the case as the mortality rate was low in LMICs.

There is a lack of data in the South-South region on the structure and presentation of COVID-19 cases in Rivers State. Additionally, what are the demographics of infected people in the community ^{d'}, [analyse des données de COVID-19 dans l'état de state River au Nigeria d'avril 2020à mars 2021-maladie-était-elle-concentrée-et comment-s'est-elle-manifestée ? Cette étude a répondu à ces questions](#). where²⁰

2. MATERIALS AND METHODS / EXPERIMENTAL DETAILS / **METHODOLOGY**

This study is a report of COVID-19 cases during the peak period (April 2020 to March 2021) of the pandemic in Rivers State, Nigeria. Secondary data was collected from the Department of Epidemiology, Rivers State Department of Public Health, Ministry of Health, in December 2022.

Data were entered into Microsoft Excel 2010 (Microsoft Corp, Washington, USA) and analyzed with Statistical Product and Service Solutions (SPSS) version 25 (IBM, Armonk, New York, USA).

Descriptive statistics such as frequencies, percentages, means, and standard deviations were used to summarize the data. The association between participant characteristics was analyzed using the chi-square test. The results were presented in tabular form.

The inclusion criteria were complete secondary data of people identified, diagnosed, monitored and treated for COVID-19 between April 2020 and March 2021, while the exclusion criteria were incomplete data.

Ethical approval was obtained from the Rivers State Ministry of Health Ethics Committee and the University of Port Harcourt Ethics Committee.

Comment [D10]: The type of study, study population and study period are missing, which are not well defined. The methodology lacks substance in content.

3. RESULTS AND DISCUSSION

Table 1 shows the demographics of patients who have had COVID-19 in Rivers State.

Of the seven thousand thirty-eight patients (7,083), only six thousand two hundred and ninety-nine (6,299) had complete data. More men were infected than women with a M:F of 3:1. 57% of those infected were in the fifth and sixth age groups and 70.8% had at least post-secondary education. Three-fifths were diagnosed at home and 85.8% were diagnosed at the COVID-19 center at the Rivers State University Teaching Hospital (RSUTH).

Mortality from COVID-19 in Rivers State was 1.4%.

Table 1. Demographics of people infected with COVID-19 between April 2020 and March 2021

Variables	Frequency	Percentage
Gender		
Male	4817	76.5
Female	1482	23.5
age range		
1-10	96	1.5
11-20	515	8.2
21-30	907	14.4
31-40	2060	32.7
41-50	1655	26.3
51-60	738	11.7
61-70	237	3.8
71-80	68	1.1
81-90	21	0.3

>90	2	0.0
Education		
No formality	1296	20.6
Nursery	18	0.3
Primary	289	4.6
Secondary	236	3.7
Postsecondary	3330	52.9
Tertiary	11:30 a.m.	17.9
Diagnostic centers		
Rivers State University Teaching Hospital (RSUTH)	964	13.9
Port Harcourt University Teaching Hospital (UPTH)	344	4.9
Other health facilities	1575	22.7
Home	4070	58.5
Hospitalization		
Yes	1395	22.1
No	4904	77.9
Laboratory centers		
Rivers State University Teaching Hospital (RSUTH)	5403	85.8
Port Harcourt University Teaching Hospital (UPTH)	424	6.7
SPDC Molecular Laboratory	218	3.5
INDORAMA molecular laboratory	83	1.3
Other government-approved laboratories	171	2.7
Mortality		
Alive	6211	98.6

Dead	88	1.4
Total	6299	100.0

Mean age = 38.63 ± 13.37 years, Median = 38 years, SEM = 0.17, V = 178.67

Table 2 shows that 1 in 3 infected men were in the 31-40 age group and 3 in 10 men were in the 41-50 age group, while for women, 1 in 5 women and 1 In 4 women who were infected were infected were in the age groups 21-30 and 31-40 years respectively. The association between age and sex was statistically significant.

Table 2. Association between sex and age group of all people infected with COVID-19 between April 2020 and March 2021

Variables	Frequency	Percentage	Frequency	Percentage	Frequency	Percentage	<i>P</i> .
Sex	Male		Female		Total		
Age groups (years)							<0.001
1-10	57	1.2	39	2.6	96	1.5	
11-20	267	5.5	248	16.7	515	8.2	
21-30	604	12.5	303	20.5	907	14.4	
31-40	1675	34.8	385	25.9	2060	32.7	
41-50	1412	29.3	243	16.4	1655	26.3	
51-60	578	12.0	160	10.8	738	11.7	
61-70	171	3.6	66	4.5	237	3.8	
71-80	42	0.9	26	1.8	68	1.1	
81-90	11	0.2	ten	0.7	21	0.3	
>90	0	0.0	2	0.1	2	0.0	

Total	4817	100.0	1482	100.0	6299	100.0
--------------	-------------	--------------	-------------	--------------	-------------	--------------

Table 3 shows that most people infected with COVID-19 lived in urban LGAs in Rivers State.

Table 3. Geographic distribution of people infected with COVID-19 between April 2020 and March 2021


Variables	Frequency	Percentage
Geographical distribution by LGA		
Obio/Akpor	1888	30.0
Port Harcourt	3998	63.5
Eleme	258	4.1
Beautiful	80	1.3
Ikwerre	12	0.2
Oyigbo	12	0.2
Others	51	0.8
Total	6299	100.0

Table 4 shows some of the symptoms exhibited by infected people. 76.9% of patients presented at least one sign/symptom. A fifth had a dry cough, a tenth had a fever and a third had dysphagia, bleeding gums, malaise and anorexia. 6% suffered from ammonia.


Table 4. Some signs and symptoms presented by people infected with COVID-19 between April 2020 and March 2021

Variables	Frequency	Percentage
------------------	------------------	-------------------

Symptoms		
Yes	4843	76.9
Abdominal symptoms		
Yes	6	0.1
Dysphagia		
Yes	1976	31.4
Chest pain		
Yes	73	1.2
Chills/Sweats		
Yes	11	0.2
Confusion		
Yes	3	0.0
Dry cough		
Yes	1289	20.5
Cough + sputum		
Yes	391	6.2
Cough + blood		
Yes	46	0.7
Fever		
Yes	604	9.6
Headache		
Yes	270	4.3
Bleeding gums		
Yes	1976	31.4



Articular pain		
Yes	7	0.1
Lung fluid (auscultation and x-rays)		
Yes	5	0.1
Faintness		
Yes	1976	31.4
Stiff neck		
Yes	61	1.0
Hematemesis		
Yes	77	1.2
Loss of appetite		
Yes	1976	31.4
Vomiting		
Yes	39	0.6
Conjunctivitis		
Yes	5	0.1
Acute respiratory syndrome		
Yes	16	0.3
Loss of taste		
Yes	5	0.1
Loss of smell		
Yes	378	6.0
Enlarged lymph nodes		
Yes	47	0.7



Wheezing		
Yes	37	0.6
Inability to walk		
Yes	36	0.6
Flail Chest		
Yes	36	0.6
Oxygen saturation below 94		
Yes	1978	31.4
Total	6229	100.0

Discussion

It is said that pandemics are not gender neutral.²⁰⁻²³ The demographics of people infected with COVID-19 have changed as the pandemic has progressed. There has been a shift from the older age group to the younger ones. A study from the United Kingdom reported an increase in excess hospitalizations since August 1, 2020 among women aged 20 to 40.²⁴ Among patients admitted to hospital, 49 (12.0%) were aged 21 to 30, compared to 33 (8.1%) aged 41 to 50 and 35 (8.6%) aged 61 to 69 years. Of the men admitted to hospital, only 17 (3.7%) were in the age group of 21 to 30 years.²⁴ Studies have shown that serious illness and mortality are higher overall in men aged over 60 years.²⁵ The one-year report of people infected with COVID-19 in Rivers State, Nigeria showed that among infected women, 303 (20.5%) were aged 21-30 years, compared to 243 (16.4%) aged 41 to 50 years, and 66 (4.5%) aged 61 to 70 years. Among the infected men, 604 (12.5%) were in the age group of 21 to 30 years.

The Rivers State COVID-19 report showed a mean age of 38.63 ± 13.37 and that males were 3 times more infected than females. This could be attributed to the fact that many men are breadwinners, travel a lot, wash their hands less and have underlying medical conditions.²⁶ This may also be due to biological differences

between the two sexes, since studies have shown that women have stronger immune systems than men.²⁷ Studies in other regions of the world have also reported male dominance.²⁸⁻³² A study that reported COVID data from 10 European countries found that women diagnosed with COVID-19 outnumbered men, although working-age people showed a reversal of the trend. around retirement.³³ It further reported that infection rates among women in the 60 to 69 age group have declined and resulted in crossover with infection rates among men. Furthermore, women's relative disadvantage peaks between ages 20 and 29, while men's relative disadvantage peaks between ages 70 and 79.³⁴ High infection rates among working-age women have been attributed to the likelihood that they occupy a greater share of health and care-related occupations in the prime working age groups.³⁵ The same factors that determine women's higher life expectancy explain their lower mortality rates and higher male disadvantage at older ages.³³

As in other countries, most of those infected came from urban areas. COVID-19 started in urban communities before spreading to rural areas.³⁴ This can be attributed to their lifestyle and wealth. Many can afford to travel to other countries and, in fact, some have found themselves stuck in these countries during the pandemic.^{35,36} Additionally, urban areas are high-density areas with many leisure centers and clubs.³⁷ Thus, the ease of spread was rapid among them.

Rivers State Covid data showed that 31.4% of those infected experienced sore throat, bleeding gums, malaise and loss of appetite. 9.6% had a fever. The most common symptom presented in the state was sore throat. This compares to the study carried out in China by Guan et al which reported the same thing.³⁸ Other studies have reported different types of symptoms. A study of 41 patients in China found that 98% and 76% had fever and cough, respectively.³⁹ Another study reported 26% fever and 17.4% sore throat among the participants.⁴⁰ Jin-jin Zhang et al reported 917% fever and 75% cough among participants.⁴¹

4. CONCLUSION

Men were three times more infected than women, and the COVID-19 mortality rate during the reported year was 1.4%.

Comment [D11]: More detail must be given in the conclusion to highlight the methodology in relation to the results obtained according to the objectives.

CONSENT (IF APPLICABLE)

"All authors declare that 'written informed consent was obtained from the patient (or other approved parties) for the publication of this case report and accompanying images. A copy of the written consent is available for review by the editorial board/the editor-in-chief/the editorial board. members of this journal.'"

ETHICS APPROVAL (IF APPLICABLE)

Ethics Committees of the University of Port Harcourt and Rivers State Ministry of Health Ethics Council.

THE REFERENCES

1. Covid WHO. Dashboard. Geneva: World Health Organization 2020 @ <https://covid19.who.int>. Reviewed on December 22, 2023.
2. Lone SA, Ahmad A. COVID-19 pandemic – an African perspective. *Emerging microbes and infections*. 2020; 9(1):1300-1308.
3. Mohd HA, Al-Tawfiq JA, Memish ZA. Origin of Middle East respiratory syndrome coronavirus (MERS-CoV) and animal reservoir. *Journal of Virology*. 2016; 13:1-7
4. Shrotri M, Swinnen T, Kampmann B, Parker EP. An interactive website that tracks COVID-19 vaccine development. *The Lancet Global Health*. 2021; 9(5): e590-2.
5. MassingaLoembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AE, Nkengasong JN. COVID-19 in Africa: spread and response. *Natural medicine*. 2020; 26(7):999-1003.
6. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. *Nature examines immunology*. 2021; 21(8):469-470.

7. Garba B, Zakaria Z, Salihu MD, Bande F, Saidu B, Bala JA. Breaking the COVID-19 transmission cycle: a challenge for Nigeria. *Journal of Global Health*. 2020; 10(2).
8. Muhammad DG, Ahmad HY, Umar R. *JAT XML*. *Women's Health*. 2021; 3:37-55.
9. Ogundokun RO, Lukman AF, Kibria GB, Awotunde JB, Aladeitan BB. Predictive modeling of confirmed COVID-19 cases in Nigeria. *Modeling of infectious diseases*. 2020; 5:543-8.
10. Odunayo B.J. On monitoring the coronavirus disease 2019 (covid-19) pandemic outbreak in Nigeria. *African Journal of Biology and Medical Research*. 2020;3(2):33-40.
11. Mathieu E, Ritchie H, Rodés - Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus (COVID-19) pandemic. *Our world in data*. March 5, 2020.
12. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, Zheng M et al. An overview of COVID-19. *Journal of Zhejiang University. Science. B*. May 2020;21(5):343.
13. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. *Science*. 2021; 371(6524):27-28.
14. Kavanagh MM, Erondu NA, Tomori O, Dzau VJ, Okiro EA, Maleche A et al. Access to vital medical resources for African countries: testing and response to COVID-19, ethics and policy. *The Lancet*. 2020; 395(10238):1735-1738.
15. MassingaLoembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AE, Nkengasong JN. COVID-19 in Africa: spread and response. *Natural medicine*. July 2020;26(7):999-1003.
16. Moore M, Gelfeld B, Okunogbe A, Paul C. Identifying future disease hotspots: infectious disease vulnerability index. *Rand Health Quarterly*. 2017; 6(3).
17. Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M et al. Why are morbidity and mortality from COVID-19 low in Africa? *The American Journal of Tropical Medicine and Hygiene*. 2020;103(2):564.
18. Adegboye OA, Adekunle AI, Pak A, Gayawan E, Leung DH, Rojas DP et al. Change in the epicenter of the epidemic and its impact on the import risks of COVID-19 progression: a modeling study. *Travel medicine and infectious diseases*. 2021; 40:101988.
19. Betsch C, Wieler LH, Habersaat K. Monitoring COVID-related behavioral insights-The Lancet. 2020; 395(10232):1255-6.
20. Campisi T, Basbas S, Skoufas A, Kaltsidis A, Tesoriere G. The impact of COVID-19 is not gender neutral: regional-scale changes in modal choices in Sicily. *Transport research procedure*. 2023; 69:584-91.
21. Koontalay A, Suksatan W, Prabsangob K, Sadang JM. The burden of healthcare workers during the COVID-19 pandemic: a qualitative systematic review. *Journal of Multidisciplinary Health Care*. 2021; 3015-25.
22. Simba H, Ngcobo S. Are pandemics gender neutral? Women's health and COVID-19. *Frontiers in women's health around the world*. 2020; 1:570666.

23. Morgan R, Davies SE, Feng H, Gan CC, Grépin KA, Harman S et al. Using gender analysis matrices to integrate a gender perspective into infectious disease outbreak research. *Health policy and planning*. 2022; 37(7):935-41.
24. Venkatesan P. The changing demographics of COVID-19. *Lancet Respiratory Medicine*. 2020; 8(12): e95.
25. Sobotka T, Brzowska Z, Muttarak R, Zeman K, Di Lego V. Age, gender and COVID-19 infections. *MedRxiv*. 2020: 2020-05.
26. Betron M, Gottert A, Pulerwitz J, Shattuck D, Stevanovic-Fenn N. Men and COVID-19: adding a gender perspective. *Global public health*. 2020; 15(7):1090-2.
27. Khan AR, Ratele K. Men and Covid-19: Explaining the need for masculinity analysis. *Journal of Positive Community Practices*. 2021; 1(1):3-7.
28. Mukherjee S, Pahan K. Is COVID-19 gender sensitive? *Journal of Neuroimmune Pharmacology*. 2021; 16:38-47.
29. Ambrosino I, Barbagelata E, Ortona E, Ruggieri A, Massiah G, Giannico OV et al. Gender differences in patients with COVID-19: a narrative review. *Monaldi Arch Chest Dis* 2020; 90(2).
30. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. *Biol Sex Differs* 2020; 11:29 a.m.
31. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM et al. Gender differences in patients with COVID-19: focus on severity and mortality. *Public Health Front* 2020; 8:152
32. TNCPERE Team. The epidemiological characteristics of an outbreak of novel coronavirus disease (COVID-19) in 2019. *China CDC Weekly* 2020; 2: 113-122
33. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ et al. Clinical characteristics of 140 patients infected with SARS- CoV- 2 in Wuhan, China. *Allergy*. 2020;75(7):1730-41.
34. Cuadros DF, Branscum AJ, Mukandavire Z, Miller FD, MacKinnon N. Dynamics of the COVID-19 outbreak in urban and rural United States. *Annals of Epidemiology*. 2021; 59:16-20.
35. Huang Q, Jackson S, Derakhshan S, Lee L, Pham E, Jackson A et al. Urban-rural differences in COVID-19 exposures and outcomes in the South: A preliminary analysis from South Carolina. *PloS one*. 2021;16(2): e0246548.
36. Gupta D, Biswas D, Kabiraj P. COVID-19 outbreak and urban dynamics: regional variations in India. *GeoJournal*. 2022; 87(4):2719-37.
37. Acuto M. COVID-19: Lessons for an urban world (izing). *A land*. 2020; 2(4):317-9.
38. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of coronavirus disease 2019 in China. *New England Journal of Medicine*. 2020; 382(18):1708-20.

39. Mehta AA, Haridas N, Belgundi P, Jose WM. A systematic review of clinical and laboratory parameters associated with increased severity in patients with COVID-19. Diabetes and metabolic syndrome: research and clinical reviews. 2021; 15(2):535-41.
40. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Yet et al. Clinical characteristics of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020; 395(10223):497-506.
41. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with pneumonia infected with 2019 novel coronavirus in Wuhan, China. Jama. 2020; 323(11):1061-9.

UNDER PEER REVIEW